...first nine months of this year, the company said on Tuesday.
Zentiva, one of the largest pharmaceutical firms in central Europe, said consolidation of its Turkish business in the third quarter hurt all margins, while continued underperformance in its home market due to price erosion hampered sales.
The company, 25 percent owned by France's Sanofi-Aventis , forecast nine-month earnings before interest and tax (EBIT) of 1.46 billion crowns.
The nine-month results are due for release on Nov. 5, when the company will also give an update on the outlook for the full year.
[PRAGUE/Reuters/Finance.cz]